Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 137Breast Neoplasms 10Neoplasm Metastasis 8Neoplasms 5Bulbo-Spinal Atrophy, X-Linked 5Triple Negative Breast Neoplasms 4Salivary Gland Neoplasms 2Prostate Adenocarcinoma 2Osteoporosis 2Lower Urinary Tract Symptoms 2Hirsutism 2Thrombocytosis 1Stage I Prostate Adenocarcinoma AJCC v7 1Stage I Prostate Adenocarcinoma 1Sexual Dysfunction, Physiological 1Recurrence 1Primary Myelofibrosis 1Primary Dysautonomias 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Non Castrate Metastatic Prostate Cancer 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1

Interventions

bicalutamide 2Mifepristone 2Metformin 2Corlux 2drospirenone and ethinyl estradiol combination 1Magnesium 1Folic Acid 1Flutamide 1Ethinyl Estradiol 1Cyproterone acetate, ethinyl estradiol drug combination 1Cyproterone Acetate 1Carnitine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Hirsutism × bicalutamide × Clear all
NCT00959335 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

NCT00960310 2017-03-28

Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fed Conditions

Sandoz

Phase 1 Completed
36 enrolled
Genitourinary

Hirsutism, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡